Welcome to our dedicated page for Aptose Bioscienc news (Ticker: APTOF), a resource for investors and traders seeking the latest updates and insights on Aptose Bioscienc stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aptose Bioscienc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aptose Bioscienc's position in the market.
Rhea-AI Summary
Aptose Biosciences has secured a new loan agreement with Hanmi Pharmaceutical for up to US$8.5 million to advance the development of tuspetinib (TUS) in triple drug therapy for acute myeloid leukemia (AML). The loan will support the ongoing TUSCANY Phase 1/2 clinical trial, which combines TUS with azacitidine and venetoclax for newly diagnosed AML patients ineligible for induction chemotherapy. Tuspetinib is an oral medication targeting multiple kinases including SYK, FLT3, KIT, JAK1/2, and RSK2. Early trial data from initial cohorts has shown promising results with complete responses and minimal residual disease negativity across patients with various mutations, while maintaining a favorable safety profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.59%
Tags
-
Rhea-AI Summary
Aptose Biosciences, a clinical-stage precision oncology company, has secured a short-term cash advance from CEO Dr. William G. Rice to cover immediate obligations including payroll and continue development of tuspetinib, their oral kinase inhibitor. The advance is non-interest bearing, unsecured, and repayable without penalty. Despite this funding, Aptose warns it may face insolvency proceedings without additional funding in the coming days. The company also announced the resignation of board member Carol Ashe, effective June 16, 2025. The cash advance constitutes a related-party transaction under MI 61-101, though Aptose is exempt from formal valuation and minority shareholder approval requirements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-29.52%
Tags
-
Rhea-AI Summary
Aptose Biosciences presented promising clinical data from its TUSCANY Phase 1/2 trial evaluating tuspetinib (TUS) in combination with venetoclax and azacitidine for newly diagnosed AML patients. The study included 10 patients across three dosage cohorts (40mg, 80mg, 120mg). In the 40mg cohort, three patients achieved complete remissions with MRD-negativity. The 80mg cohort showed 100% composite complete remissions, while the 120mg cohort patients remain under treatment. Notably, the treatment demonstrated efficacy across diverse genetic populations, including challenging cases with TP53 mutations. The triplet therapy showed favorable safety with no dose-limiting toxicities, no treatment-related deaths, and all patients remaining alive. The trial continues at 10 leading U.S. clinical sites with expected enrollment of 18-24 patients by mid-late 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.78%
Tags
Rhea-AI Summary
Aptose Biosciences (OTC: APTOF), a clinical-stage precision oncology company, held its annual and special meeting on May 27, 2025, with 57.90% shareholder participation. All nominated directors were successfully re-elected with strong approval ratings above 97%. Shareholders approved key proposals including: an advisory resolution on executive compensation, amendments to the 2021 stock incentive plan, and a potential reverse stock split at a ratio between 1-for-2 to 1-for-20. The meeting was adjourned to allow time to find a successor auditor to KPMG LLP. The company is developing a tuspetinib (TUS) based triple drug frontline therapy for newly diagnosed acute myeloid leukemia (AML) patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.57%
Tags
-
Rhea-AI Summary
Aptose Biosciences has announced significant progress in its Phase 1/2 TUSCANY trial, evaluating tuspetinib (TUS) in combination with venetoclax and azacitidine for newly diagnosed AML patients. The Cohort Safety Review Committee (CSRC) has approved dose escalation from 80mg to 120mg of TUS following positive safety and efficacy data from initial cohorts. The trial has shown complete remissions (CRs) and minimal residual disease (MRD)-negativity across diverse mutations, with no significant safety concerns or dose-limiting toxicities. Notably, the treatment demonstrated effectiveness in difficult-to-treat populations, including patients with TP53 and RAS mutations. The TUSCANY trial, conducted at 10 leading U.S. clinical sites, aims to enroll 18-24 patients by mid-late 2025. Updated data will be presented at the European Hematology Association Congress in June 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.07%
Tags
-
Rhea-AI Summary
Aptose Biosciences (OTC: APTOF) has been selected to present data from its TUSCANY Phase 1/2 clinical trial at the EHA Congress 2025 in Milan. The trial evaluates tuspetinib (TUS) in combination with venetoclax and azacitidine as a triplet therapy for newly diagnosed AML patients ineligible for chemotherapy. Initial results from the 40mg and 80mg dose cohorts have shown promising outcomes, including safety, complete remissions, and MRD negativity across diverse mutations, particularly in TP53-mutated/CK AML and FLT3-wildtype AML patients. The study is ongoing at 10 leading U.S. clinical sites, with expected enrollment of 18-24 patients by mid-late 2025. The TUS+VEN+AZA triplet is being developed as the only safe and mutation agnostic frontline therapy for treating diverse populations of newly diagnosed AML patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.49%
Tags
Rhea-AI Summary
Aptose Biosciences reported Q1 2025 financial results and progress in its TUSCANY clinical trial for tuspetinib (TUS) in combination with venetoclax and azacitidine for frontline AML treatment. The trial showed promising results with 6 out of 7 patients achieving complete remissions across two dose cohorts (40mg and 80mg). Notably, two patients with TP53 mutations showed positive responses. The company reported a reduced net loss of $5.5M compared to $9.6M in Q1 2024, with cash reserves of $4.7M as of March 31, 2025. However, current funding only supports operations until end of May 2025. Aptose was delisted from Nasdaq in April 2025 and now trades on OTC Markets (APTOF) and TSX (APS). Research and development expenses decreased to $2.3M from $6.4M year-over-year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.45%
Tags
FAQ
What is the current stock price of Aptose Bioscienc (APTOF)?
The current stock price of Aptose Bioscienc (APTOF) is $0.8438 as of June 24, 2025.
Aptose Bioscienc
OTC:APTOF
APTOF Rankings
APTOF Stock Data
2.04M